We additionally interrogated public databases to identify biomarkers which may be associated with ICB therapy response and identified that MTSCC-like tumors harbor high PD-L1 expression which may be supportive of ICB therapy in this rare tumor subtype. The gene discussed is CD274; the disease is neoplasm.